Neonatal Bone Anomalies Prompt FDA Warning About Off-label Use of Magnesium Sulfate

According to a safety announcement from the FDA, administering magnesium sulfate injection to stop preterm labor in pregnant women -- an off-label use of the drug -- for longer than five-seven days may lead to low calcium levels and bone problems in the developing fetus, including osteopenia and fractures. The agency also noted that the shortest duration of treatment that can result in harm to an infant is not known at this time.
Source: AAFP Health of the Public - Category: Primary Care Source Type: news